Zacks.com on MSN
Beyond GLP-1: Eli Lilly's Expanding Drug Portfolio Lifts Sales
LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...
Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...
Zacks Investment Research on MSN
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and ...
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Eli Lilly and Company (NYSE: LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...
Eli Lilly’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.
Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...
Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...
Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...
In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...
Hidden homeowner costs climb to nearly $16,000 a year, Eli Lilly approaches trillion-dollar status amid weight-loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results